Skip to main content
ONCY
NASDAQ Life Sciences

Oncolytics Biotech Faces Nasdaq Delisting After Stock Sinks Below $1

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.82
Mkt Cap
$96.939M
52W Low
$0.77
52W High
$1.51
52W Position info
6.5% above low
Off High info
46% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ONCY is trading near its 52-week low of $0.77 (6.5% above the low).

Summary

Oncolytics Biotech received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement, with a 180-day compliance period ending January 19, 2027.


Key Events · Legal and Risk Events · ONCY

  • Nasdaq Delisting Notice Received

    On July 20, 2026, Oncolytics Biotech received a notice from Nasdaq that its stock had closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement.

  • 180-Day Compliance Period

    The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.

  • Potential Additional Extension

    If the company fails to regain compliance within the initial 180 days, it may be eligible for an additional 180-day period, provided it meets certain market value and listing standards.

  • Delisting Risk Amid Financial Strain

    The delisting notice adds to existing pressures, including a going concern warning and ongoing ATM dilution, with the stock currently trading at $0.82.


Analysis · ONCY · Life Sciences

A Nasdaq delisting notice landed on July 20, 2026, after Oncolytics Biotech's stock closed below $1.00 for 30 consecutive business days. The company now has 180 days, until January 19, 2027, to regain compliance by sustaining a closing bid price of at least $1.00 for ten consecutive business days. Should it fall short, delisting could follow, though an additional 180-day extension may be available if certain conditions are met. This development compounds existing pressures—a going concern warning and ongoing ATM dilution—raising the stakes for upcoming clinical and regulatory milestones.

At the time of this filing, ONCY was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.9M. The 52-week trading range was $0.77 to $1.51. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ONCY - Latest Insights

ONCY
Jul 20, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.865
Real-time Price: $0.820 info
Change: -$0.045 (-5%) info
Market Cap: $96.939M info
ONCY
Jul 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9152
Real-time Price: $0.820 info
Change: -$0.0952 (-10%) info
Market Cap: $96.939M info
ONCY
Jul 13, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.820 info
Change: -$0.110 (-12%) info
Market Cap: $96.939M info
ONCY
Jul 13, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.820 info
Change: -$0.110 (-12%) info
Market Cap: $96.939M info
ONCY
Jul 08, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.799
Real-time Price: $0.820 info
Change: +$0.021 (+3%) info
Market Cap: $96.939M info